This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.

The MarketWatch News Department was not involved in the creation of this content. Results of 244-Patient Study to Support Planned FDA Pre-Market Approval (PMA) Application BOSTON and YOKNEAM, Israel, ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH).

Men experiencing bothersome urinary symptoms should consult their urologist early. Based on prostate anatomy, symptom severity, and overall health, an appropriate treatment plan--including MISTs--can ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Patients with gout, especially those younger than 60 years, have an increased risk for benign prostatic hyperplasia (BPH), according to a study published online Dec. 26 in Diagnostics. Woo Jin Bang, ...

BPH is a natural enlargement of the prostate. 50 percent of men in their 50′s will have this condition, along with 80 percent of men in their 80′s. Frequent need to use the bathroom is a common side ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE ...